Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907374 · ClinicalTrials.gov registry record · NA
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
A NA study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00907374 is a NA study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 46 participants.
The verdict
NCT00907374, a NA study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing of the progression of atherosclerotic disease (measured by carotid intima media thickness \[CIMT\]).
Interventions
- DRUG benazepril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907374
The ClinicalTrials.gov registry entry for NCT00907374 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which benazepril is the first listed.
NCT00907374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00907374 about?
NCT00907374 is a clinical study titled "Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria". The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (mea...
What is the current status of trial NCT00907374?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2005-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00907374?
The interventions under investigation include: benazepril (DRUG).
Who is sponsoring clinical trial NCT00907374?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.